BSE Live
Mar 23, 11:14Prev. Close
37.37
Open Price
36.63
Bid Price (Qty.)
38.11 (5000)
Offer Price (Qty.)
36.63 (307511)
NSE Live
Mar 23, 11:12Prev. Close
37.36
Open Price
36.62
Bid Price (Qty.)
36.80 (1)
Offer Price (Qty.)
36.62 (391016)
| Cash Flow of Take Solutions (in Rs. Cr.) | Mar 05 | Mar 04 | |
| 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 0.00 | 0.00 | |
| Net CashFlow From Operating Activities | 0.00 | 0.00 | |
| Net Cash Used In Investing Activities | 0.00 | 0.00 | |
| Net Cash Used From Financing Activities | 0.00 | 0.00 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 0.00 | 0.00 | |
| Cash And Cash Equivalents Begin of Year | 0.00 | 0.00 | |
| Cash And Cash Equivalents End Of Year | 0.00 | 0.00 |
01.01.2026
14.06.2024
Take Solutions Consolidated March 2024 Net Sales at Rs 13.21 crore, down 64.82% Y-o-Y
22.02.2024
Take Solutions Consolidated December 2023 Net Sales at Rs 16.85 crore, down 68.56% Y-o-Y
09.11.2023
Take Solutions Consolidated September 2023 Net Sales at Rs 18.09 crore, down 59.69% Y-o-Y
14.06.2024
Take Solutions Consolidated March 2024 Net Sales at Rs 13.21 crore, down 64.82% Y-o-Y
22.02.2024
Take Solutions Consolidated December 2023 Net Sales at Rs 16.85 crore, down 68.56% Y-o-Y
09.11.2023
Take Solutions Consolidated September 2023 Net Sales at Rs 18.09 crore, down 59.69% Y-o-Y
16.08.2023
Take Solutions Standalone June 2023 Net Sales at Rs 5.42 crore, down 59.51% Y-o-Y
23.03.2026
Alkem Laboratories gets DCGI nod for Semaglutide Injection; share price fall marginally
23.03.2026
22.03.2026
Sell-on-rise market? SBI Securities sees Nifty under pressure, picks two stocks for the week ahead
20.03.2026
Eris Lifesciences, Natco Pharma to launch generic Ozempic at 90% cheaper price
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth